Latest Breaking News On - Joshua brumm - Page 4 : comparemela.com

Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials

Company's cash position remains strong, R&D expenses increase, and net loss widens

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

- Initial ACHIEVE and DELIVER Data to be Presented at a Company Event Around the J.P. Morgan Healthcare Conference in Early January 2024, Including Safety, Biomarker of Splicing and Functional Outcome.

Why Shares of Dyne Therapeutics Fell This Week

Insiders sold more than 15,000 shares of company stock on Tuesday.

Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., Aug. 03, 2023 .